Form 4: PVCT CEO Converts Note to Preferred Stock

PROVECTUS BIOPHARMACEUTICALS CEO Edward Pershing converted an 8% unsecured convertible promissory note into Series D-1 Convertible Preferred Stock.

Summary

• Edward Pershing, CEO and Director of PROVECTUS BIOPHARMACEUTICALS, INC. (PVCT), reported a change in beneficial ownership via a Form 4 filing.
• On October 16, 2025, an 8% unsecured convertible promissory note (the "2024 Note") with a principal amount of $50,000 was converted.
• The conversion occurred at a price of $2.862 per share of Series D-1 Convertible Preferred Stock, resulting in the acquisition of 18,880 shares of Series D-1 Convertible Preferred Stock.
• Each share of Series D-1 Preferred Stock is convertible into 10 shares of the Issuer's common stock, par value $0.001 per share.
• The Series D-1 Convertible Preferred Stock will automatically convert into Common Stock on June 20, 2026, unless converted earlier.
• Following this transaction, Pershing beneficially owns a total of 1,095,000 shares of Series D-1 Convertible Preferred Stock and 2,503,379 shares of Common Stock.

Sentiment

Score: 6

Explanation: The conversion of a convertible note into equity by a CEO is generally a neutral to slightly positive signal, as it reduces debt and increases insider equity stake, indicating continued commitment. However, it's a pre-scheduled event, not a new investment decision.

Positives

• CEO Edward Pershing converted an existing debt instrument into equity, indicating continued commitment to the company's long-term prospects.
• The conversion of the 2024 Note reduces the company's outstanding debt obligations.

Negatives

• The future conversion of Series D-1 Preferred Stock into common stock could lead to dilution for existing common shareholders.

Risks

• Potential future dilution of common stock upon the automatic conversion of Series D-1 Convertible Preferred Stock on June 20, 2026, or earlier, as each preferred share converts into 10 common shares.

Future Outlook

The Series D-1 Convertible Preferred Stock held by Edward Pershing is scheduled for automatic conversion into Common Stock on June 20, 2026, unless converted earlier according to its terms.

Industry Context

This Form 4 filing is a standard disclosure of an insider's equity transaction, specifically the conversion of a convertible note. It does not provide broader industry trends or competitive analysis. Such conversions are common mechanisms for debt-to-equity restructuring or insider equity accumulation in the biotechnology sector.

Stakeholder Impact

• Shareholders: Potential future dilution of common stock upon the conversion of Series D-1 Preferred Stock into common shares.
• Creditors: Reduction in outstanding debt obligations due to the conversion of the 2024 Note.

Next Steps

• Automatic conversion of Series D-1 Convertible Preferred Stock into Common Stock on June 20, 2026.

Key Dates

Keywords

PROVECTUS BIOPHARMACEUTICALS, PVCT, Form 4, Insider Transaction, Convertible Note, Preferred Stock, Edward Pershing, CEO, Director, Equity Conversion, Beneficial Ownership